DME Archives - Insight Presented by Prime Creative Media Fri, 06 May 2022 04:00:46 +0000 en-US hourly 1 https://www.insightnews.com.au/wp-content/uploads/2024/02/cropped-Insight-favicon-32x32.png DME Archives - Insight 32 32 New anti-VEGF therapies seeking Aussie approval https://www.insightnews.com.au/new-anti-vegf-therapies-seeking-aussie-approval/ Mon, 09 May 2022 20:00:30 +0000 https://www.insightnews.com.au/?p=27225
The approval is based on the 48-week results of PULSAR and PHOTON trials.

The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens are seeking approval to list the treatments on the Australian PharmaceuticalRead More

The post New anti-VEGF therapies seeking Aussie approval appeared first on Insight.

]]>
The approval is based on the 48-week results of PULSAR and PHOTON trials.
The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens are seeking approval to list the treatments on the Australian Pharmaceutical
Read More

The post New anti-VEGF therapies seeking Aussie approval appeared first on Insight.

]]> Roche’s faricimab meets primary endpoint in DME trial https://www.insightnews.com.au/roches-faricimab-meets-primary-endpoint-in-dme-trial/ Mon, 11 Jan 2021 22:50:15 +0000 http://www.insightnews.com.au/?p=18537
The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.

The post Roche’s faricimab meets primary endpoint in DME trial appeared first on Insight.

]]>
The American Medical Association’s United States Adopted Names (USAN) Council, with the WHO, approved the name.
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but
Read More

The post Roche’s faricimab meets primary endpoint in DME trial appeared first on Insight.

]]> Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange https://www.insightnews.com.au/tax-credit-strengthens-optheas-balance-sheet-follows-au175m-ipo-on-us-exchange/ Tue, 17 Nov 2020 21:26:01 +0000 http://www.insightnews.com.au/?p=17802
The ATO's R&D Tax Incentive enables companies to receive 43.5% of eligible research and development expenditure.

The post Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange appeared first on Insight.

]]>
The ATO's R&D Tax Incentive enables companies to receive 43.5% of eligible research and development expenditure.
Melbourne biopharmaceutical company Opthea has received an $8.5 million research and development (R&D) tax credit from the Australian tax authority ahead of pivotal Phase 3 trials of its lead drug
Read More

The post Tax credit strengthens Opthea’s balance sheet; follows AU$175m IPO on US exchange appeared first on Insight.

]]> Opthea becomes ASX top 300 company https://www.insightnews.com.au/opthea-becomes-asx-top-300-company/ Mon, 29 Jun 2020 21:21:05 +0000 http://www.insightnews.com.au/?p=15361
Opthea's share price has soared more than 250% during the past year.

The post Opthea becomes ASX top 300 company appeared first on Insight.

]]>
Opthea's share price has soared more than 250% during the past year.
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met primary end points in the latest clinical trial for diabetic macular edema
Read More

The post Opthea becomes ASX top 300 company appeared first on Insight.

]]> Opthea progresses DME trials despite COVID-19 disruption https://www.insightnews.com.au/opthea-progresses-dme-trials-despite-covid-19-disruption/ Mon, 06 Apr 2020 23:27:25 +0000 http://www.insightnews.com.au/?p=14087
CEO Dr Megan Baldwin was grateful to have reached the clinical milestone.

The post Opthea progresses DME trials despite COVID-19 disruption appeared first on Insight.

]]>
CEO Dr Megan Baldwin was grateful to have reached the clinical milestone.
Results are imminent in biopharmaceutical company Opthea’s latest clinical trial evaluating the safety and efficacy of its lead drug candidate with Eylea in diabetic macular edema (DME) patients. The
Read More

The post Opthea progresses DME trials despite COVID-19 disruption appeared first on Insight.

]]> Sleep apnoea linked to diabetic macular oedema https://www.insightnews.com.au/sleep-apnoea-linked-to-diabetic-macular-oedema/ Tue, 07 Jan 2020 00:57:26 +0000 http://www.insightnews.com.au/?p=13136

The post Sleep apnoea linked to diabetic macular oedema appeared first on Insight.

]]>
New research has drawn a link between severe sleep apnoea and diabetic macular oedema, firming up the connection between the two conditions. The effects of sleep apnoea are widespread due to the way the
Read More

The post Sleep apnoea linked to diabetic macular oedema appeared first on Insight.

]]>